Please use this identifier to cite or link to this item:
http://hdl.handle.net/11375/26238Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Iba T | - |
| dc.contributor.author | Levy JH | - |
| dc.contributor.author | Connors JM | - |
| dc.contributor.author | Warkentin TE | - |
| dc.contributor.author | Thachil J | - |
| dc.contributor.author | Levi M | - |
| dc.date.accessioned | 2021-02-24T17:02:00Z | - |
| dc.date.available | 2021-02-24T17:02:00Z | - |
| dc.date.issued | 2020-12 | - |
| dc.identifier.issn | 1364-8535 | - |
| dc.identifier.issn | 1364-8535 | - |
| dc.identifier.uri | http://hdl.handle.net/11375/26238 | - |
| dc.description.abstract | Thrombotic complications and coagulopathy frequently occur in COVID-19. However, the characteristics of COVID-19-associated coagulopathy (CAC) are distinct from those seen with bacterial sepsis-induced coagulopathy (SIC) and disseminated intravascular coagulation (DIC), with CAC usually showing increased D-dimer and fibrinogen levels but initially minimal abnormalities in prothrombin time and platelet count. Venous thromboembolism and arterial thrombosis are more frequent in CAC compared to SIC/DIC. Clinical and laboratory features of CAC overlap somewhat with a hemophagocytic syndrome, antiphospholipid syndrome, and thrombotic microangiopathy. We summarize the key characteristics of representative coagulopathies, discussing similarities and differences so as to define the unique character of CAC. | - |
| dc.publisher | Springer Science and Business Media LLC | - |
| dc.rights | This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. | - |
| dc.rights.uri | 2 | - |
| dc.subject | Antiphospholipid syndrome | - |
| dc.subject | COVID-19 | - |
| dc.subject | Coagulopathy | - |
| dc.subject | Disseminated intravascular coagulation | - |
| dc.subject | Hemophagocytic syndrome | - |
| dc.subject | Thrombotic microangiopathy | - |
| dc.subject | Betacoronavirus | - |
| dc.subject | Blood Coagulation Disorders | - |
| dc.subject | Blood Coagulation Tests | - |
| dc.subject | COVID-19 | - |
| dc.subject | Coronavirus Infections | - |
| dc.subject | Humans | - |
| dc.subject | Inflammation Mediators | - |
| dc.subject | Pandemics | - |
| dc.subject | Platelet Aggregation | - |
| dc.subject | Pneumonia, Viral | - |
| dc.subject | SARS-CoV-2 | - |
| dc.title | The unique characteristics of COVID-19 coagulopathy | - |
| dc.type | Article | - |
| dc.date.updated | 2021-02-24T17:01:58Z | - |
| dc.rights.license | Attribution - CC BY | - |
| dc.identifier.doi | https://doi.org/10.1186/s13054-020-03077-0 | - |
| Appears in Collections: | Faculty Publications (via McMaster Experts) | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| The unique characteristics of COVID-19 coagulopathy.pdf | Published version | 964.84 kB | Adobe PDF | View/Open |
Items in MacSphere are protected by copyright, with all rights reserved, unless otherwise indicated.
